Outcome markers for clinical trials in cerebral amyloid angiopathy. - sprookjes - yvandenbroek - TriplyDB

Outcome markers for clinical trials in cerebral amyloid angiopathy.

Outcome markers for clinical trials in cerebral amyloid angiopathy.

http://www.wikidata.org/entity/Q33859442

about

Ischemic brain injury in cerebral amyloid angiopathy Amyloid positron emission tomography in sporadic cerebral amyloid angiopathy: A systematic critical update Risk factors are different for deep and lobar remote hemorrhages after intravenous thrombolysis.Blood-brain barrier dysfunction and cerebral small vessel disease (arteriolosclerosis) in brains of older people.Structural network alterations and neurological dysfunction in cerebral amyloid angiopathy.Mapping the landscape of cerebral amyloid angiopathy research: an informetric analysis perspective.Clinical Neuropathological Analysis of 10 Cases of Cerebral Amyloid Angiopathy-Related Cerebral Lobar Hemorrhage.No neuropathological evidence for a direct topographical relation between microbleeds and cerebral amyloid angiopathy.The H-ATOMIC Criteria for the Etiologic Classification of Patients with Intracerebral Hemorrhage.Taxifolin inhibits amyloid-β oligomer formation and fully restores vascular integrity and memory in cerebral amyloid angiopathy.Statin Therapy and the Development of Cerebral Amyloid Angiopathy--A Rodent in Vivo Approach.White matter hyperintensity patterns in cerebral amyloid angiopathy and hypertensive arteriopathy.Consensus statement for diagnosis of subcortical small vessel disease.Longitudinal decrease in blood oxygenation level dependent response in cerebral amyloid angiopathy Impact of sex and APOE4 on cerebral amyloid angiopathy in Alzheimer's disease.Prognostic value of copeptin in patients with acute stroke.Thrombolysis-related intracerebral hemorrhage and cerebral amyloid angiopathy: accumulating evidence.The increasing impact of cerebral amyloid angiopathy: essential new insights for clinical practice.Rodent Models of Vascular Cognitive Impairment.Identification of neurovascular changes associated with cerebral amyloid angiopathy from subject-specific hemodynamic response functions.Emerging concepts in sporadic cerebral amyloid angiopathy.Reduced vascular amyloid burden at microhemorrhage sites in cerebral amyloid angiopathy.William M. Feinberg Award for Excellence in Clinical Stroke: Big Pictures and Small Vessels.Total Magnetic Resonance Imaging Burden of Small Vessel Disease in Cerebral Amyloid Angiopathy: An Imaging-Pathologic Study of Concept Validation Context is everything: From cardiovascular disease to cerebral microbleeds.Perivascular spaces on 7 Tesla brain MRI are related to markers of small vessel disease but not to age or cardiovascular risk factors.Progression of Brain Network Alterations in Cerebral Amyloid Angiopathy.Development of Cerebral Microbleeds in the APP23-Transgenic Mouse Model of Cerebral Amyloid Angiopathy-A 9.4 Tesla MRI Study.Florbetapir-PET to diagnose cerebral amyloid angiopathy: A prospective study.Total small vessel disease burden and brain network efficiency in cerebral amyloid angiopathy.Cerebral amyloid angiopathy research: on the verge of an explosion?MRI-visible perivascular space location is associated with Alzheimer's disease independently of amyloid burden.Microbleed and microinfarct detection in amyloid angiopathy: a high-resolution MRI-histopathology study.Cerebral Amyloid Angiopathy-Related Inflammation Biomarkers: Where are we Now?Core CSF biomarker profile in cerebral amyloid angiopathy: A meta-analysis.Diagnosis of Cerebral Amyloid Angiopathy: Evolution of the Boston Criteria.

P2860

Q30945201-587954FD-545E-4C16-9C32-5E53A3A19970 Q33700069-9B1E66BE-2BD7-409B-8694-F6699EAC2665 Q33825171-46EB0244-5A60-4EED-A9F4-A25F9E821AA4 Q34406773-96230E1B-AFE5-48E9-B6D4-59302EE46F46 Q34842317-D9A1344A-5EEB-4AEE-BCED-E4DBA20C5113 Q35662754-A7FD0AC5-3971-4DBA-A855-283D7009EB0F Q35947644-AA06C194-9086-4B94-9CCE-78FB37467494 Q35949979-0295E138-24A6-4AFF-B55E-1DBF163E8A62 Q36044903-E335F27D-98CB-4187-B9BB-BC2CC7FA915E Q36335013-313FC02A-6F41-487B-9C1E-843933FA5AC2 Q36512688-9F9E22EB-F7E0-4B03-9C13-5565F1429032 Q36580370-3C79DEF6-E758-4556-8DC4-85C4C55F592E Q36593206-E4026E91-799B-408D-9C33-C2177309352B Q36787347-42CEA2F3-C4E2-41A9-BF15-01D08E8E220F Q38407944-F79354DC-33A2-4DA8-818D-345F62B97CE1 Q38417376-C9041ACB-D114-4183-B809-4294B534E390 Q38501128-CEC3B453-BCC3-4650-BC0E-6E6339EB793A Q38636940-D43C225B-9D67-4A65-B112-A1B0FF16FB9D Q38920987-98BBC803-701C-4852-98F8-C5815A40DACA Q38987236-2F1ED255-2973-49E0-BDB1-14CB6342EDFC Q39196370-B220CED5-DFA6-4099-B294-368CD3A9ED00 Q39258014-2C705493-7804-464E-A8EA-FA5FBED08368 Q39429330-00CC2213-C0CD-41D3-8FDB-E6D361F4523B Q39639734-DC08740F-6123-45E6-8034-D9BB19823A7E Q40041578-FEAD6C82-1134-4B26-A46F-77BF590A0632 Q41551627-42EC9EED-636F-4373-B800-FE4DF073428D Q41657749-0AE471BA-0FC2-4770-BA2E-4EE2E92795C4 Q42095705-B098F1A3-FE73-4FB8-95FD-5F976868C301 Q45425671-3AFD05DB-13F3-4FF8-BAF4-30F7623BF71D Q47982433-9E3B6DA6-CE66-4153-854A-2477EB4D4DCC Q48118577-4537EEA7-C394-406B-AE6A-42DC21A0CFF0 Q48248949-9B8416F6-6C04-4A65-8148-698B86299989 Q48505035-C72CA1D8-A6BA-4F98-98BA-84990A73EFBD Q49013361-ED733CB5-B537-44CB-8866-612B2233CE91 Q49545848-C8759B57-D8D2-4F63-8A1C-4F3639BA80A3 Q50043256-7949BEF5-2B77-4802-9CA1-C6AA93F8210D

P2860

Outcome markers for clinical trials in cerebral amyloid angiopathy.

http://www.wikidata.org/entity/Q33859442

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Outcome markers for clinical trials in cerebral amyloid angiopathy.

@ast

Outcome markers for clinical trials in cerebral amyloid angiopathy.

@en

type

label

Outcome markers for clinical trials in cerebral amyloid angiopathy.

@ast

Outcome markers for clinical trials in cerebral amyloid angiopathy.

@en

prefLabel

Outcome markers for clinical trials in cerebral amyloid angiopathy.

@ast

Outcome markers for clinical trials in cerebral amyloid angiopathy.

@en

P1433

Q33859442-96B997C1-6B6C-435D-ABF3-ADF3EF8F29F4

P1476

Q33859442-FED2E6A7-172F-4E05-A9D8-A17F9E2D46EE

P2093

Q33859442-19BA9F21-1BB5-4961-9DB5-BC26994CB866

Q33859442-7043701D-AB0F-4328-953A-8F5906F3B16D

Q33859442-914471B2-5575-41BC-9E62-DA06E0281EA2

Q33859442-E3F27505-AB7A-47FA-A536-07B13B2476AF

Q33859442-F133AA48-FD05-40E7-8C29-FB23822C756B

Q33859442-F8014FCD-137F-425A-A9CC-8C75091EB6D1

Q33859442-FCC55700-FA54-4635-A436-61AE008AC6C6

P2860

Q33859442-04C8CF3E-3059-4105-82E4-A8DE04EF9A92

Q33859442-05594792-8771-49E4-8FCB-26C095629AC5

Q33859442-0594057E-A546-4F22-800C-6AFF3538A22E

Q33859442-059ED21D-82A2-466F-8447-FA0EF6430F9F

Q33859442-0A694D45-5CFC-4E53-A91B-667DA3579A0F

Q33859442-0A706A70-439F-4B3E-AAD1-B047A6B8C2B8

Q33859442-0E336471-BA4E-491D-BA77-DD693D527FA4

Q33859442-1049CCDC-A68A-4CEE-B789-5EBE11A0D6AF

Q33859442-165375CA-767C-4B5A-8B9B-7C6D7BCD587B

Q33859442-16910CCC-194C-469E-B17F-06FAC1CEEEE4

P304

Q33859442-580D863A-4D37-4055-8EE0-A0C18E9858A7

P31

Q33859442-EA7E36DE-B782-4675-B788-4131702643E0

P356

Q33859442-DDF77C91-7D35-4A6C-B97E-7BD44912325C

P433

Q33859442-445C011F-3CA3-4FDA-96D1-95CFA348F992

P478

Q33859442-5984DFFD-5750-40E2-86ED-0A9DD4EA1210

P50

Q33859442-CC12AE66-C92D-4F89-B661-732DEC5D58EA

Q33859442-D7923617-A8DA-4931-A3BE-BF8B4F844895

Q33859442-DD24A079-FF6B-4710-8DEF-0B03C3B1725D

Q33859442-F1754361-4425-414B-A7FC-47BB5AF94878

P577

Q33859442-A6D3DBC6-F015-4673-9F72-2A87B73480C0

P698

Q33859442-BD22A897-377C-4843-BE93-8D2661420985

P932

Q33859442-F329D1A1-8127-456E-8F05-0AF23A0EF7BE

P356

S1474-4422(14)70003-1

P1433

Lancet Neurology

P1476

Outcome markers for clinical trials in cerebral amyloid angiopathy.

@en

P2093

David J Werring

http://www.w3.org/2001/XMLSchema#string

Eric E Smith

http://www.w3.org/2001/XMLSchema#string

Geert Jan Biessels

http://www.w3.org/2001/XMLSchema#string

Julie A Schneider

http://www.w3.org/2001/XMLSchema#string

Mark van Buchem

http://www.w3.org/2001/XMLSchema#string

Meike Vernooij

http://www.w3.org/2001/XMLSchema#string

Steven M Greenberg

http://www.w3.org/2001/XMLSchema#string

P2860

Use of Florbetapir-PET for Imaging β-Amyloid Pathology

Cerebral microinfarcts: the invisible lesions

The Alzheimer's disease neuroimaging initiative: progress report and future plans

Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration.

Susceptibility-weighted imaging is more reliable than T2*-weighted gradient-recalled echo MRI for detecting microbleeds.

Abeta-induced vascular oxidative stress and attenuation of functional hyperemia in mouse somatosensory cortex.

Cerebral microbleeds: a guide to detection and interpretation.

Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study

Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy.

Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS).

P304

419-428

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1474-4422(14)70003-1

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Charlotte Cordonnier

Rustam Al-Shahi Salman

P577

2014-02-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24581702

http://www.w3.org/2001/XMLSchema#string

P932

4085787

http://www.w3.org/2001/XMLSchema#string